Affordable Access

Publisher Website

Reforming pharmaceutical industry-physician financial relationships: lessons from the United States, France, and Japan.

Authors
  • 1
Type
Published Article
Journal
The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
1748-720X
Publication Date
Volume
39
Issue
4
Pages
662–670
Identifiers
DOI: 10.1111/j.1748-720X.2011.00633.x
PMID: 22084852
Source
Medline

Abstract

This article compares the means that the United States, France, and Japan use to oversee pharmaceutical industry-physician financial relationships. These countries rely on professional and/or industry ethical codes, anti-kickback laws, and fair trade practice laws. They restrict kickbacks the most strictly, allow wide latitude on gifts, and generally permit drug firms to fund professional activities and associations. Consequently, to avoid legal liability, drug firms often replace kickbacks with gifts and grants. The paper concludes by proposing reforms that address problems that persist when firms replace kickbacks with gifts and grants based on the experience of the three countries.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments